Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Gentium S.p.A. (Nasdaq: GENT)

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD and Fast Track Designation by the U.S. FDA to treat VOD. About VOD Veno-occlusive disease (VOD) is a potentially life-threatening condition, which typically occurs as a result of a significant complication of stem cell transplantation. Certain high-dose conditioning regimens used as part of stem cell transplants (SCT) can damage the lining cells of hepatic blood vessels and result in VOD, a blockage of the small veins of the liver that leads to liver failure and can result in significant dysfunction of other organs such as the kidneys and lungs (so-called severe VOD). SCT is a frequently used treatment modality following high-dose chemotherapy and radiation therapy for hematologic cancers and other conditions in both adults and children. There is currently no approved agent for the treatment or prevention of VOD in the United States or the European Union. *

 

Period Start 2001-07-01 renamed
  Group Jazz Pharmaceuticals (Group)
Products Industry cardiovascular drug
  Industry 2 cancer drug
Persons Person Islam, Khalid (Gentium 200912– CEO before Arpida 199907–200805 CEO)
  Person 2 Calabrese, Salvatore (MolMed 201809– CFO before Gentium CFO 2005–2014 + Novopharma SpA + PriceWaterhouseCoopers)
     
Region Region Como (CO)
  Country Italy
  Street 2 Piazza XX Settembre
  City 22079 Villa Guardia (CO)
  Tel +39-031-385999
    Address record changed: 2020-12-02
     
Basic data Employees C: 51 to 100 (2007-12-31)
  Currency EUR
  Annual sales 29,039,000 (revenues, total (2012) 2012-12-31)
  Profit 774,000 (2012-12-31)
  Cash 12,485,000 (2012-12-31)
     
    * Document for »About Section«: 
     
   
Record changed: 2023-07-10

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Jazz Pharmaceuticals (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News How Covid Effects the Brain 650x300px




» top